Patients and Methods We enrolled and followed-up 56 patients (age, 70.4 ± 10.9 years, mean ± SD) (HR, 3.32, 95% CI, 1.14 to 9.71; HR 2.73, 95% CI, 1.03 to 7.23, respectively 
Introduction

Anti-neutrophil cytoplasmic antibody (ANCA) -associated renal vasculitis comprises a group of heterogeneous diseases that often present with rapidly progressive glomerulonephritic syndrome. The incidence of primary renal vasculitis (PRV) does not differ between Japan and Europe (1-5).
However, the ratio of serum myeloperoxidase/proteinase 3 (MPO/PR3) ANCA among such patients in Japan is much higher than the reported European and American values (1-4). Recent nationwide Japanese surveys have demonstrated that most patients presenting with PRV (including renal limited vasculitis) are elderly with positive MPO-ANCA, and that survival rates at 6 months and 1 year after starting treatment are 74.2% and 70%, respectively (6-8). Several Euro-
T a b l e 1 . I n c l u s i o n Cr i t e r i a pean and North American investigators have examined the treatment response and prognostic factors in patients with ANCA-associated renal vasculitis (9-13). The patients described in these studies
were relatively younger than those in our previous study (1) 
Subjects and Methods
Patients
Fifty-six patients (24 T a b l e 5 . Cl i n i c a l Ch a r a c t e r i s t i c s a n d P r o g n o s i s o f t h e P a t i e n t s De v i d e d b y ANCA-t i t e r (Fig. 2) . Based on the Japanese system of grading the clinical severity of rapidly progressive glomerulonephritis (7), the survival rate became significantly poorer as the grade increased (P < 0.0001; Log-rank test) (Fig. 3) (Table 6 ).
T a b l e 2 . Cl i n i c a l S c o r e a n d Ac t i v i t y T a b l e 3 . Ad mi s s i o n Ch a r a c t e r i s t i c s
Results
Admission characteristics
F l o w c h a r t s i n d i c a t i n g r e n a l f a t e o f c o h o r t .
T a b l e 4 . Co ma r i s o n b e t we e n t h e P a t i e n t s wi t h a n d wi t h o u t Ac u t e Di a l y s i s T h e r a p y
Discussion
The ratio of MPO/PR3-ANCA is very high in Japan compared with that of Europe or USA (1-4). However, to our knowledge, no English language report has addressed the outcome of Japanese PRV patients, except for one questionnaire (8). The characteristics of our patients were as follows: All of those with onset of new PRV in a restricted area over the past 5 years were included; all were closely monitored until follow-up information was collected in De-
F i g u r e 2 . Ka p l a n -Me i e r p l o t i n d i c a t i n g u n a d j u s t e d s u r v i v a l p r o b a b i l i t y a c c o r d i n g t o a g e ( a ) , g e nd e r ( b ) , p r e s e n c e o f l u n g l e s i o n s ( c ) a n d a c u t e d i a l y s i s t h e r a p y ( d ) . Di f f e r e n c e s i n s u r v i v a l c u r v e s
we r e a n a l y z e d b y l o g -r a n k t e s t . v i v a l r a t e s b a s e d o n g r a d i n g o f c l i n i c a l  s e v e r i t 14) . This could be because a high ratio of our patients was elderly and dialysis-dependent. As in other recently published series (10, (19) (20) (21) showing that the age of patients with ANCA-associated vasculitis is increasing, the median age of our patients was 72 years and 63% were aged 70 years or older. The 2-year mortality rate of 36% among our patients was similar to the findings of others (9-13) with an older population and severe renal impairment, highlighting the importance of age and renal function for survival. The renal survival rate of 72% among our patients was also similar to those found by others ( T a b l e 6 . Mu l t i v a r i a t e An a l y s i s o f F a c t o r s Co n f e r r i n g P o o r e r S u r v i v a (10, 22, 23, 24 Table 5 , the patients with low ANCA-titers showed higher age and lower CRP levels compared to those with high ANCA-titers, but the difference was not significant. In addition, about half of the MPO-ANCA-positive patients in our series, similar to the reported ratio (9, 12, 14, 15, 29) , had no extra-renal involvement, although renal limited vasculitis (RLV) comprises a separate entity within the ANCA-associated vasculitides (23, 28, 29 
l Ra t e s u p o n P RV P a t i e n t s u s i n g t h e Co x P r o p o r t i o n a l -h a z a r d s
